National Institutes of Health

Tulane University, established in 1834 and located in New Orleans, Louisiana, is a prominent independent research university recognized for its academic rigor and selectivity. As a member of the Association of American Universities, Tulane offers a wide range of undergraduate, graduate, and professional degrees across various fields, including liberal arts, science and engineering, architecture, business, law, social work, medicine, and public health. The university is noted for its extensive research activities, supported by specialized centers such as the Tulane Cancer Center and the Newcomb College Institute. Managed by an executive team and overseen by a board of trustees, Tulane's endowment fund plays a crucial role in funding scholarships, professorships, and research initiatives, contributing to its status as a leader in higher education. Tulane's commitment to scholarly excellence is reflected in its classification by the Carnegie Foundation as a university with “very high research activity,” placing it among the top 2 percent of institutions in the nation.

Tulane University School of Medicine, part of the renowned Tulane University founded in 1834 in New Orleans, focuses on advancing medical education and research. The school offers a comprehensive range of programs, including undergraduate and graduate medical education, a biomedical sciences graduate program, and continuing education services. It is dedicated to fostering innovation and entrepreneurship within the medical field, equipping students with the necessary skills for leadership in healthcare. Additionally, Tulane School of Medicine provides various doctoral, master's, and graduate certificate programs, contributing to the development of future medical professionals and scholars.

AxoSim, Inc. is a biotechnology company based in New Orleans, Louisiana, specializing in the development of innovative platforms for neurological drug discovery. Founded in 2014, AxoSim focuses on accelerating the drug development process by providing advanced in vitro models that mimic the human nervous system. Its key technologies include Nerve-on-a-Chip, which predicts clinical neurotoxicity and models human neurodegenerative diseases, and NerveSim, which features human-relevant Schwann cell myelination and electrical metrics. Additionally, AxoSim offers BrainSim, a platform that supports oligodendrocyte myelination for testing in neurotoxicity. By creating 3D cell-based models that replicate the structure and function of nerve tissue, AxoSim aims to enhance the efficiency of pharmaceutical research while reducing reliance on traditional animal testing methods.

AxoSim, Inc. is a biotechnology company based in New Orleans, Louisiana, specializing in the development of innovative platforms for neurological drug discovery. Founded in 2014, AxoSim focuses on accelerating the drug development process by providing advanced in vitro models that mimic the human nervous system. Its key technologies include Nerve-on-a-Chip, which predicts clinical neurotoxicity and models human neurodegenerative diseases, and NerveSim, which features human-relevant Schwann cell myelination and electrical metrics. Additionally, AxoSim offers BrainSim, a platform that supports oligodendrocyte myelination for testing in neurotoxicity. By creating 3D cell-based models that replicate the structure and function of nerve tissue, AxoSim aims to enhance the efficiency of pharmaceutical research while reducing reliance on traditional animal testing methods.

AxoSim, Inc. is a biotechnology company based in New Orleans, Louisiana, specializing in the development of innovative platforms for neurological drug discovery. Founded in 2014, AxoSim focuses on accelerating the drug development process by providing advanced in vitro models that mimic the human nervous system. Its key technologies include Nerve-on-a-Chip, which predicts clinical neurotoxicity and models human neurodegenerative diseases, and NerveSim, which features human-relevant Schwann cell myelination and electrical metrics. Additionally, AxoSim offers BrainSim, a platform that supports oligodendrocyte myelination for testing in neurotoxicity. By creating 3D cell-based models that replicate the structure and function of nerve tissue, AxoSim aims to enhance the efficiency of pharmaceutical research while reducing reliance on traditional animal testing methods.

Tulane University, established in 1834 and located in New Orleans, Louisiana, is a prominent independent research university recognized for its academic rigor and selectivity. As a member of the Association of American Universities, Tulane offers a wide range of undergraduate, graduate, and professional degrees across various fields, including liberal arts, science and engineering, architecture, business, law, social work, medicine, and public health. The university is noted for its extensive research activities, supported by specialized centers such as the Tulane Cancer Center and the Newcomb College Institute. Managed by an executive team and overseen by a board of trustees, Tulane's endowment fund plays a crucial role in funding scholarships, professorships, and research initiatives, contributing to its status as a leader in higher education. Tulane's commitment to scholarly excellence is reflected in its classification by the Carnegie Foundation as a university with “very high research activity,” placing it among the top 2 percent of institutions in the nation.

AxoSim, Inc. is a biotechnology company based in New Orleans, Louisiana, specializing in the development of innovative platforms for neurological drug discovery. Founded in 2014, AxoSim focuses on accelerating the drug development process by providing advanced in vitro models that mimic the human nervous system. Its key technologies include Nerve-on-a-Chip, which predicts clinical neurotoxicity and models human neurodegenerative diseases, and NerveSim, which features human-relevant Schwann cell myelination and electrical metrics. Additionally, AxoSim offers BrainSim, a platform that supports oligodendrocyte myelination for testing in neurotoxicity. By creating 3D cell-based models that replicate the structure and function of nerve tissue, AxoSim aims to enhance the efficiency of pharmaceutical research while reducing reliance on traditional animal testing methods.